1. Search Result
Search Result
Results for "

SOD1

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

1

Isotope-Labeled Compounds

5

Antibodies

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W115718
    Cuprizone
    3 Publications Verification

    Dopamine β-hydroxylase Neurological Disease
    Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) [1].
    Cuprizone
  • HY-132580
    Tofersen
    2 Publications Verification

    BIIB067; ISIS-SOD1Rx; ISIS 333611

    SOD Neurological Disease
    Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis [1] .
    Tofersen
  • HY-16074
    ATN-224
    4 Publications Verification

    Bischolinetetrathiomolybdate

    SOD Cancer
    ATN-224 is an orally active Cu 2+/Zn 2+-superoxide dismutase 1 (SOD1) inhibitor. ATN-224 inhibits SOD1 activity in endothelial cells, an effect that is dose dependent with an IC50 of 17.5 nM.
    ATN-224
  • HY-132580A
    Tofersen sodium
    2 Publications Verification

    BIIB067 SODium; ISIS-SOD1Rx SODium; ISIS 333611 SODium

    SOD Neurological Disease
    Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis [1] .
    Tofersen sodium
  • HY-115445
    LCS-1
    3 Publications Verification

    Apoptosis SOD Cancer
    LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC50 value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells [1] .
    LCS-1
  • HY-W073128

    PFTeDA

    PPAR Apoptosis PGC-1α AMPK Akt mTOR Reactive Oxygen Species (ROS) Endocrinology
    Perfluorotetradecanoic acid (PFTeDA) is an orally active perfluoroalkyl substance. Perfluorotetradecanoic acid directly binds to the ligand-binding domain of purified hPPARγ, with a Kd value of 157.8 μM. Perfluorotetradecanoic acid significantly reduces the activity of the SIRT1/PGC1α and AMPK signaling pathways while stimulating the activity of the AKT1/mTOR signaling pathway. Perfluorotetradecanoic acid significantly upregulates the expression of corticosterone biosynthesis genes. Perfluorotetradecanoic acid increases ROS levels and promotes Apoptosis. Perfluorotetradecanoic acid impairs Leydig cell function and male reproductive endocrine function in adult male rats [1] .
    Perfluorotetradecanoic acid
  • HY-RS13559

    Small Interfering RNA (siRNA) Others

    SOD1 Human Pre-designed siRNA Set A contains three designed siRNAs for SOD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SOD1 Human Pre-designed siRNA Set A
    SOD1 Human Pre-designed siRNA Set A
  • HY-123982

    SOD Neurological Disease
    SOD1-Derlin-1 inhibitor-2 (compound 56-59) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-2 attenuates the interactions between Derlin-1 and SOD1 mut. SOD1-Derlin-1 inhibitor-2 can be used for the research of amyotrophic lateral sclerosis (ALS) [1].
    SOD1-Derlin-1 inhibitor-2
  • HY-138131

    SOD Neurological Disease
    SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1 G93A-Derlin-1 complex with an IC50 value of 7.11 μM. SOD1-Derlin-1 inhibitor-1 can be used for the research of amyotrophic lateral sclerosis [1].
    SOD1-Derlin-1 inhibitor-1
  • HY-153019

    SOD Neurological Disease
    NUCC-0000323 is a potent superoxide dismutase 1 (SOD1) inhibitor. NUCC-0000323 inhibits SOD1 expression. NUCC-0000323 can be used in research of amyotrophic lateral sclerosis (ALS) [1].
    NUCC-0000323
  • HY-173025

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 12 (Compound 37) is the agonist for nuclear receptor-associated protein 1 (Nurr1) that activates the transcriptional activity of Nurr1 with an EC50 of 0.06 μM. Nurr1 agonist 12 activates the human response elements NBRE, NurRE, and DR5 with EC50 of 0.07 μM, 0.027 μM, and 0.014 μM, respectively. Nurr1 agonist 12 induces the expression of Nurr1-regulated neurotrophic genes, such as tyrosine hydroxylase (TH), SOD1/2, BDNF, Sestrin 3, and BIRC5 (Survivin). Nurr1 agonist 12 exhibits neuroprotective efficacy against Paraquat-induced neurotoxicity [1].
    Nurr1 agonist 12
  • HY-E70377

    Cu/Zn SOD

    SOD Inflammation/Immunology Cancer
    Cu/Zn Superoxide dismutase (Cu/Zn SOD; SOD1) is a cytosolic copper-zinc dimer form of superoxide dismutase enzyme. Cu/Zn Superoxide dismutase has oxygen radical enzymatic dismutation [1].
    Cu/Zn Superoxide dismutase
  • HY-P10627

    Amyloid-β Neurological Disease
    SOD1 (147-153) human is a peptide fragment of Cu/Zn superoxide dismutase (SOD1) with a high propensity to form amyloid fibrils. SOD1 (147-153) human may trigger the aggregation of full-length SOD1 and is a common molecular determinant of familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS) [1].
    SOD1 (147-153) human
  • HY-RS16926

    Small Interfering RNA (siRNA) Others

    Sod1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sod1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sod1 Mouse Pre-designed siRNA Set A
    Sod1 Mouse Pre-designed siRNA Set A
  • HY-161612

    Tyrosinase SOD COX NO Synthase Keap1-Nrf2 Inflammation/Immunology
    Mycosporine 2 glycine is an anti-inflammatory agent and TYRP1 inhibitor. Mycosporine 2 glycine inhibits the expression of inflammatory genes and reduces nitric oxide production. Mycosporine 2 glycine binds tightly to the active pocket of TYRP1 and inhibits the activity of melanogenesis-related enzymes. Mycosporine 2 glycine can be used in the research of hyperpigmentation and inflammation-related diseases [1] .
    Mycosporine 2 glycine
  • HY-RS23369

    Small Interfering RNA (siRNA) Others

    Sod1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sod1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sod1 Rat Pre-designed siRNA Set A
    Sod1 Rat Pre-designed siRNA Set A
  • HY-176827

    SOD Neurological Disease
    SOD1-IN-1 (comppund 9) is a potent SOD1 inhibitor. SOD1-IN-1 shows no cytotoxicity [1].
    SOD1-IN-1
  • HY-179533

    SOD Neurological Disease
    SOD1-aggregation-IN-1 (compound 20) is a potent SOD aggregation inhibitor. SOD1-aggregation-IN-1 inhibits MG132 (HY-13259)-induced mutant SOD1 intracellular aggregation in PC12-SOD1 G85R YFP cells with an EC50 of 2.63 μM. SOD1-aggregation-IN-1 can be used for amyotrophic lateral sclerosis (ALS) research [1].
    SOD1-aggregation-IN-1
  • HY-148901

    SOD Neurological Disease
    CMB-087229 is a mutant superoxide dismutase 1 (SOD1) protein aggregation inhibitor with IC50 of 67 nM, which can be used in the research of amyotrophic lateral sclerosis [1].
    CMB-087229
  • HY-W115718R

    Reference Standards Dopamine β-hydroxylase Neurological Disease
    Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) [1].
    Cuprizone (Standard)
  • HY-132580S

    BIIB067-d27; ISIS-SOD1Rx-d27; ISIS 333611-d27

    Isotope-Labeled Compounds SOD Neurological Disease
    Tofersen-d27 (BIIB067-d27) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.
    Tofersen-d27
  • HY-172152

    FKBP Calcium Channel Neurological Disease
    MP-010 is a FKBP12 ligand that regulates cytosolic calcium by stabilizing RyR channel activity. MP-010 promotes functional improvement in SOD1 G93A amyotrophic lateral sclerosis (ALS) mice, as evidenced by improved motor coordination, increased integrity of neuromuscular junctions, and significantly enhanced survival of spinal motor neurons. MP-010 can be used for research in the field of neurological diseases [1].
    MP-010
  • HY-145294

    ROCK Neurological Disease
    ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation [1].
    ROCK2-IN-5
  • HY-163772

    Keap1-Nrf2 Neurological Disease
    Fraxinellone analog 1 (compound 2) is a potent and rapid activator of the Nrf2 mediated antioxidant defense system, which protects against glutamate-mediated excitotoxicity and induces the expression of antioxidant genes Gpx4, Sod1, and Nqo1. Fraxinellone analog 1 has neuroprotective effects and regulatory effects against oxidative stress and inflammation, and can be used in the study of neurodegenerative diseases [1].
    Fraxinellone analog 1
  • HY-182648

    Neurological Disease
    K811 is an orally active ASK1 inhibitor with an IC50 of 6 nM. K811 inhibits glial cell activation in the lumbar spinal cord of SOD1 G93A transgenic mice. K811 extends the survival of SOD1 G93A transgenic mice, a mouse model of amyotrophic lateral sclerosis. K811 can be used in studies related to amyotrophic lateral sclerosis [1].
    K811
  • HY-182304

    Amyloid-β α-synuclein Amylin Receptor Tau Protein SOD Neurological Disease
    CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) [1].
    CLR01 sodium
  • HY-182446

    NF-κB SOD Neurological Disease
    SRI-22818 is a NF-κB activator with an EC50 of 0.5 μM. SRI-22818 upregulates the expression of NF-κB and promotes its activation. SRI-22818 increases the level of SOD2. SRI-22818 exhibits activity in the SOD1 G93A model of amyotrophic lateral sclerosis (ALS). SRI-22818 can be used for research related to amyotrophic lateral sclerosis [1].
    SRI-22818

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: